KR20220062012A - 기면증 치료에 사용하기 위한 tak-925 - Google Patents

기면증 치료에 사용하기 위한 tak-925 Download PDF

Info

Publication number
KR20220062012A
KR20220062012A KR1020227011013A KR20227011013A KR20220062012A KR 20220062012 A KR20220062012 A KR 20220062012A KR 1020227011013 A KR1020227011013 A KR 1020227011013A KR 20227011013 A KR20227011013 A KR 20227011013A KR 20220062012 A KR20220062012 A KR 20220062012A
Authority
KR
South Korea
Prior art keywords
compound
subject
administration
methyl
plasma concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227011013A
Other languages
English (en)
Korean (ko)
Inventor
데보라 하트먼
레베카 에반스
헬렌 페슬
신이치로 다나카
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20220062012A publication Critical patent/KR20220062012A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227011013A 2019-09-13 2020-09-12 기면증 치료에 사용하기 위한 tak-925 Pending KR20220062012A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900298P 2019-09-13 2019-09-13
US62/900,298 2019-09-13
US202063031686P 2020-05-29 2020-05-29
US63/031,686 2020-05-29
PCT/IB2020/058483 WO2021048822A1 (en) 2019-09-13 2020-09-12 Tak-925 for use in treating narcolepsy

Publications (1)

Publication Number Publication Date
KR20220062012A true KR20220062012A (ko) 2022-05-13

Family

ID=72560858

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227011013A Pending KR20220062012A (ko) 2019-09-13 2020-09-12 기면증 치료에 사용하기 위한 tak-925

Country Status (11)

Country Link
US (1) US20220339143A1 (https=)
EP (1) EP4028004A1 (https=)
JP (1) JP2022547711A (https=)
KR (1) KR20220062012A (https=)
CN (1) CN114980892A (https=)
AU (1) AU2020346456A1 (https=)
BR (1) BR112022004587A2 (https=)
CA (1) CA3154321A1 (https=)
CO (1) CO2022004596A2 (https=)
MX (1) MX2022003018A (https=)
WO (1) WO2021048822A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220062361A (ko) * 2019-09-13 2022-05-16 다케다 야쿠힌 고교 가부시키가이샤 과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도
AU2021205892B2 (en) 2020-01-10 2026-04-23 Takeda Pharmaceutical Company Limited A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450
CN116583502A (zh) 2020-09-03 2023-08-11 欧瑞夏治疗有限公司 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途
US20240165092A1 (en) * 2021-04-02 2024-05-23 Takeda Pharmaceutical Limited Company Use of an orexin 2 receptor agonist for post operation recovery
IL316468A (en) 2022-04-22 2024-12-01 Teijin Pharma Ltd The aftermath of oxazepine
WO2024075825A1 (ja) 2022-10-07 2024-04-11 キッセイ薬品工業株式会社 シクロペンタン化合物
EP4611745A1 (en) * 2022-10-31 2025-09-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
TW202535890A (zh) 2023-10-20 2025-09-16 日商帝人製藥股份有限公司 氧氮呯衍生物之結晶或其溶劑合物之結晶
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑
WO2025229493A1 (en) * 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815134B1 (en) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
PT929574E (pt) 1996-08-27 2005-11-30 Praecis Pharm Inc Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
MX376164B (es) * 2014-10-23 2025-03-07 Eisai R&D Man Co Ltd Composiciones y metodos para tratar el insomnio.
WO2016201373A1 (en) * 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
LT3984994T (lt) * 2016-02-04 2024-10-10 Takeda Pharmaceutical Company Limited Pakeistas piperidino junginys kaip 2 tipo oreksino agonistas narkolepsijai gydyti

Also Published As

Publication number Publication date
CA3154321A1 (en) 2021-03-18
JP2022547711A (ja) 2022-11-15
EP4028004A1 (en) 2022-07-20
CN114980892A (zh) 2022-08-30
WO2021048822A1 (en) 2021-03-18
BR112022004587A2 (pt) 2022-06-14
US20220339143A1 (en) 2022-10-27
AU2020346456A1 (en) 2022-04-14
MX2022003018A (es) 2022-06-14
CO2022004596A2 (es) 2022-08-30

Similar Documents

Publication Publication Date Title
KR20220062012A (ko) 기면증 치료에 사용하기 위한 tak-925
US20220331303A1 (en) Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness
AU2018260666A1 (en) Methods and compositions for treating sleep apnea
US12594269B2 (en) Method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450
TW201328689A (zh) 治療睡眠-覺醒病症之方法
JP2018044006A (ja) 睡眠改善のための低用量ドキセピンの使用法
JP2025510295A (ja) 社会的／情動的引きこもりまたは離隔の処置のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2015509931A (ja) 医薬的な組み合わせ
CN1541092A (zh) 治疗原发性失眠的方法
Napoliello et al. Buspirone: a worldwide update
KR20230165782A (ko) 수술 후 회복을 위한 오렉신 2 수용체 작용제의 용도
TW202302100A (zh) 食慾激素２受體促效劑於治療食慾激素介導之疾病或病症之用途
US20090306050A1 (en) Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
Zerzevatcı et al. Antidepressant effects of ketamine
CN118078789B (zh) 阿托莫西汀在制备增加骨血管h亚型内皮细胞药物中的应用
CN118401239A (zh) 用于治疗抑郁症，包括难治性抑郁症的2-氟脱氯氯胺酮
JP2008514689A (ja) Ａｄｈｄ、ｃｆｓ、ｆｍおよび鬱病の処置のためのロフェプラミンの薬学的な組成物の使用
WO2024108560A1 (zh) 阿托莫西汀在制备增加骨血管h亚型内皮细胞药物中的应用
JP2023134464A (ja) 治療不応性うつ病の治療
CN1931153A (zh) 用于治疗抑郁症及相关病症的包括文拉法辛的药物组合物
EP2269600A1 (en) Treatment of sleep disorders using eplivanserin in COPD patients

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902